Skip to main content
INVENTISBIO CO., LIMITED. logo

INVENTISBIO CO., LIMITED. — Investor Relations & Filings

Ticker · 688382 ISIN · CNE100005Q22 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 445 across all filing types
Latest filing 2025-12-19 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688382

About INVENTISBIO CO., LIMITED.

https://www.inventisbio.com/

InventisBio Co., Ltd. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on addressing unmet medical needs in oncology and metabolic diseases. Its research and development pipeline includes several high-potential candidates, such as befotertinib, a third-generation EGFR tyrosine kinase inhibitor for non-small cell lung cancer, and garsorasib, a potent KRAS G12C inhibitor. Additionally, the company is developing D-0502, an oral selective estrogen receptor degrader for breast cancer, and D-0120, a selective URAT1 inhibitor for the treatment of hyperuricemia and gout. InventisBio leverages its proprietary drug discovery platform and global clinical development expertise to advance a diverse portfolio of targeted therapies aimed at improving patient outcomes through precision medicine.

Recent filings

Filing Released Lang Actions
益方生物2025年限制性股票激励计划（草案）摘要公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding a 2025 restricted stock incentive plan (股权激励计划) for a company named 益方生物科技（上海）股份有限公司. It includes comprehensive information about the stock incentive plan's purpose, scope, number of shares, eligibility, vesting conditions, pricing, accounting treatment, and procedures. The document references relevant laws and regulations such as the Company Law, Securities Law, and stock exchange rules. It is not a financial report, earnings release, or management discussion but rather a formal announcement of a capital-related plan involving issuance of restricted shares to employees and management. This type of document fits best under the category of Capital/Financing Update (CAP), as it relates to changes in capital structure and financing activities through stock incentives. The document length and detail confirm it is not a brief announcement or a simple notice but a substantive disclosure of a capital plan.
2025-12-19 Chinese
益方生物对外担保管理制度（H股上市后适用）
Governance Information Classification · 95% confidence The document is titled as a management system or policy document for external guarantees by the company 益方生物科技（上海）股份有限公司. It outlines rules, procedures, responsibilities, and governance related to the company's external guarantee activities, including decision-making processes, risk management, and disclosure obligations. There is no indication that this is a financial report, earnings release, or regulatory filing announcement. It is a detailed governance and management policy document related to corporate governance practices, specifically about external guarantees. Therefore, the most appropriate classification is Governance Information (CGR). The document length (6349 characters) and content support this classification with high confidence.
2025-12-09 Chinese
益方生物董事会秘书工作规则（H股上市后适用）
Governance Information Classification · 100% confidence The document is titled '董事会秘书工作规则' which translates to 'Board Secretary Work Rules' and is a detailed set of rules and procedures regarding the appointment, duties, qualifications, and responsibilities of the company's board secretary. It references compliance with company law, stock exchange listing rules, and governance practices. There is no financial data, earnings information, or report publication mentioned. The content focuses on governance structure and internal rules related to the board secretary role. Therefore, this document fits the category of Governance Information (CGR). The document length is over 5,000 characters and contains substantive governance content, not just an announcement or certification.
2025-12-09 Chinese
益方生物第二届董事会2025年第八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed by the board of directors of 益方生物科技（上海）股份有限公司 regarding the issuance of H shares and listing on the Hong Kong Stock Exchange. It includes detailed descriptions of the issuance plan, authorization of board members to handle related matters, amendments to company bylaws, and internal governance adjustments post-listing. The document is a formal board meeting resolution announcement, not a financial report or earnings release. It does not contain financial statements or earnings data but focuses on corporate governance and capital raising plans. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board related to company management and structure.
2025-12-09 Chinese
益方生物总经理工作制度（H股上市后适用）
Governance Information Classification · 95% confidence The document is a detailed internal governance policy titled 'General Manager Work System' for a company, specifying roles, responsibilities, and procedures for senior management, particularly the General Manager and Vice General Managers. It references company law, stock exchange listing rules, and internal management structures. There are no financial statements, earnings data, or shareholder voting results. The content focuses on management duties, authority, meeting procedures, reporting, and performance evaluation, which aligns with governance practices. It is not an announcement or a brief summary but a substantive governance document. Therefore, the most appropriate classification is Governance Information (CGR).
2025-12-09 Chinese
益方生物独立董事工作制度（H股上市后适用）
Governance Information Classification · 95% confidence The document is titled as an "Independent Director Work System (Draft)" for a company, detailing the governance structure, qualifications, rights, and duties of independent directors. It references relevant laws, regulations, and listing rules, including the Hong Kong Stock Exchange Listing Rules and Chinese securities regulations. The content focuses on governance practices, board composition, director responsibilities, and procedural rules for independent directors. There is no financial data, audit information, earnings, or capital structure updates. The document is a governance framework or internal rules document rather than a report or announcement of financial results or corporate actions. Therefore, it fits best under Governance Information (CGR).
2025-12-09 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.